全文获取类型
收费全文 | 41196篇 |
免费 | 2461篇 |
国内免费 | 754篇 |
专业分类
耳鼻咽喉 | 136篇 |
儿科学 | 345篇 |
妇产科学 | 572篇 |
基础医学 | 4204篇 |
口腔科学 | 794篇 |
临床医学 | 3468篇 |
内科学 | 4079篇 |
皮肤病学 | 563篇 |
神经病学 | 2663篇 |
特种医学 | 774篇 |
外国民族医学 | 1篇 |
外科学 | 2295篇 |
综合类 | 1058篇 |
一般理论 | 6篇 |
预防医学 | 2017篇 |
眼科学 | 322篇 |
药学 | 16285篇 |
16篇 | |
中国医学 | 2375篇 |
肿瘤学 | 2438篇 |
出版年
2024年 | 35篇 |
2023年 | 1464篇 |
2022年 | 1975篇 |
2021年 | 1921篇 |
2020年 | 2162篇 |
2019年 | 1485篇 |
2018年 | 1450篇 |
2017年 | 1680篇 |
2016年 | 1660篇 |
2015年 | 1703篇 |
2014年 | 3219篇 |
2013年 | 2689篇 |
2012年 | 2601篇 |
2011年 | 2489篇 |
2010年 | 2264篇 |
2009年 | 2188篇 |
2008年 | 1777篇 |
2007年 | 1856篇 |
2006年 | 1589篇 |
2005年 | 1239篇 |
2004年 | 1003篇 |
2003年 | 870篇 |
2002年 | 892篇 |
2001年 | 735篇 |
2000年 | 650篇 |
1999年 | 689篇 |
1998年 | 480篇 |
1997年 | 351篇 |
1996年 | 379篇 |
1995年 | 63篇 |
1994年 | 55篇 |
1993年 | 53篇 |
1992年 | 95篇 |
1991年 | 108篇 |
1990年 | 114篇 |
1989年 | 84篇 |
1988年 | 82篇 |
1987年 | 38篇 |
1986年 | 22篇 |
1985年 | 27篇 |
1984年 | 24篇 |
1983年 | 23篇 |
1982年 | 26篇 |
1981年 | 23篇 |
1980年 | 27篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1977年 | 5篇 |
1976年 | 7篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
1.
2.
3.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components. 相似文献
4.
5.
6.
《Journal of pharmaceutical sciences》2023,112(8):2212-2222
For supersaturating formulations of BCS-II compounds, which by definition have high intestinal permeability, a closed USP apparatus does not provide the necessary absorptive conditions during dissolution. To address this, an artificial gut simulator (AGS) has been constructed consisting of a 2.5 mL donor compartment in which a hollow fiber-based absorption module is suspended. Drug from donor diffuses across the hollow fiber membrane to be absorbed by the continuously flowing intraluminal receiver fluid. The membrane surface area and intraluminal fluid flow rate are tuned to obtain the physiologically observed absorption rate constant for a weakly basic, poorly water-soluble model compound, ketoconazole (KTZ). Supersaturated solutions of KTZ were generated in the donor in pH 6.5 phosphate buffer by the pH-shift method in the absence (closed system, control) and presence (open system, biorelevant) of an optimally or suboptimally tuned absorption module. Drug concentrations in the donor and intraluminal fluids were determined by in-line UV spectroscopy. The presence of an absorptive sink reduced the supersaturated solution's crystallization propensity, more so in the case of the optimally tuned AGS. This study demonstrates the significance of simulating absorption of drug at a physiological rate during dissolution studies, especially to predict the performance of formulations of BCS-II drugs. 相似文献
7.
《Vaccine》2022,40(52):7515-7519
The recent wave of COVID-19 cases has led to the potential need for booster doses. We surveyed 6,294 people and found that 87.6% reported willingness to take a booster dose, with vaccine efficacy rate being the most common reason cited to accept booster dose. Differences in acceptance rates were noted among those working in non-health related sectors, different ethnic groups as well as those who had taken viral vector vaccines. 相似文献
8.
9.
《Journal of diabetes and its complications》2022,36(8):108255
AimsThe effect of Glucagon-like peptide 1 receptor agonists (GLP1 RA) on diabetic retinopathy (DR) remains controversial. Previous reviews combined data from randomized clinical trials (RCTs) with or without cardiovascular (CV) benefits and did not address confounders, therefore may have generated misleading results. The study aimed to examine the effect of GLP1RA on DR in type 2 diabetes (T2DM) in RCTs with or without CV benefits and distinguish the effect by major confounders.MethodsWe conducted electronic searches of multiple databases and a manual search using references lists. We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM. We performed a random-effects model meta-analysis.ResultsGLP1RA was associated with an elevated risk of rapidly worsening DR in four major RCTs with CV benefits in T2DM (OR 1.23, 95 % CI 1.05–1.44). The association between GLP1 RA and DR was significant in subgroups of RCTs with length over 52 weeks (1.2, 1.00–1.43), using placebo as a comparator (1.22, 1.05–1.42). In subgroups with patients who had T2DM ≥10 years (1.19, 0.99–1.42) or with subjects enrolled from multiple countries (1.2, 0.99–1.46), the association appeared to be evident but did not reach statistical significance.ConclusionsGLP1 RA including liraglutide, semaglutide, and dulaglutide are associated with an increased risk of rapidly worsening DR in RCTs with CV benefits. Further data from clinical studies with longer follow-up purposefully designed for DR risk assessment, particularly including patients of established DR are warranted. 相似文献
10.